First-in-Human Study of BG-C0979 in Advanced Solid Tumors Initiated
BeOne Medicines has initiated Phase 1 study to evaluate BG-C0979 in adults with advanced solid tumors.
Company
Pharmaceutical intelligence for BG-C0979 with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No signals indexed for this entity yet.
No signals indexed for this entity yet.
No related entities indexed yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.